The system uses liquid nitrogen to destroy benign and cancerous tumors without surgery.
By Shula Rosen
Study Shows Israeli Cancer Treatment Reduces Recurrence of Tumors by Nearly 100%
Cancer treatments are often invasive and involve repeated hospital treatments that carry significant side effects.
An Israeli company, IceCure Medical, has developed a procedure that freezes tumors, with one Study demonstrating 100% successful outcomes.
IceCure Medical’s ProSense uses a cryoablation system that uses nitrogen to neutralize tumors by freezing them.
The system targets the tumor with concentrated liquid nitrogen to destroy benign and cancerous tumors.
Although the recent Study in Japan involved breast cancer patients, the ProSense system may have various applications and could treat tumors in the kidney, lung, liver, and bone.
The treatment is fast and minimally invasive, allowing the patients to resume their normal activities without significant recovery time after the procedure or invasive surgery.
A study in Japan showed 100% efficacy in breast cancer patients with no tumors returning after the treatment.
The Study was published in the April issue of Breast Cancer and involved 18 women with a mean age of 59 whose progress was followed 44 months after their treatment with ProSense.
The Study was a continuation of a prior pilot study and measured local control of cancer, safety, patient quality of life, patient satisfaction, and cosmetic outcomes of cryoablation for patients with early-stage breast cancer.
Dr. Hisanori Kawamoto, M.D., Ph.D. from the Department of Breast Surgery, Breast and Imaging Center at St. Marianna University School of Medicine in Japan led the Study.
Following the Study, he said, “This is a very important study in Japan, where we are experiencing an upward trend in breast cancer cases, especially among women in their late 40s to early 60s.”
He continued, “These are women who often are at very active stages of their life and therefore there is a growing demand for treatment options that minimize the chance of or avoid hospitalization, in addition to resulting in favorable clinical and cosmetic outcomes. We are very pleased with these results and are hopeful that ProSense® may become a favored option in Japan upon regulatory approval for early-stage breast cancer.”